On March 21st, the Awarding Ceremony for “Innovation Star Cup” China In Vitro Diagnostics Outstanding Innovation Products was held at the Nanchang Greenland International Conference Center. The exclusive product “Heparin Binding Protein (HBP) Determination Kit” (Fluorescence Immunoassay) independently developed by JOINSTAR "Won the Gold Award for Innovative Product Reagents."
Sepsis, severe sepsis and septic shock are important clinical problems in critical care. As the population ages, the incidence of cancer increases, and the invasive medical treatment increases, the incidence of sepsis continues to rise. Every year, millions of sepsis patients are added globally, and more than a quarter of them die. As a predictor of sepsis and a causative factor, heparin-binding protein can identify patients with sepsis earlier and help to get effective treatment, which greatly reduces the incidence of sepsis, reduces medical expenditure and cost, and improves patient survival.
The five-year research and development of Heparin Binding Protein (HBP) Assay Kit by JOINSTAR provides a simple, fast and effective test for the medical industry and critically ill medicine. It is committed to building a benchmark in the field of infection and escorting public health.